Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | KIF11 | P52732 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764793 | 0.95 | TP53 (0.58) | TP53MAPTSMN1; SMN2ABCG2KIF11 | |
| SCHEMBL11912895 | 0.92 | KIF11 (0.59) | TP53MAPTSMN1; SMN2ABCG2KIF11 | |
| SCHEMBL9961950 | 0.92 | KIF11 (0.63) | TP53MAPTABCG2KIF11LMNA | |
| SCHEMBL9961949 | 0.92 | KIF11 (0.63) | TP53MAPTABCG2KIF11LMNA | |
| SCHEMBL8402724 | 0.91 | KIF11 (0.55) | TP53MAPTSMN1; SMN2ABCG2KIF11 | |
| SCHEMBL763913 | 0.91 | ABCG2 (0.60) | TP53MAPTSMN1; SMN2ABCG2KIF11 | |
| SCHEMBL764923 | 0.91 | TP53 (0.66) | TP53MAPTSMN1; SMN2ABCG2KIF11 | |
| SCHEMBL764584 | 0.91 | TP53 (0.67) | TP53MAPTSMN1; SMN2ABCG2KIF11 | |
| SCHEMBL8402733 | 0.91 | KIF11 (0.60) | TP53MAPTSMN1; SMN2ABCG2KIF11 | |
| SCHEMBL765206 | 0.90 | KIF11 (0.57) | TP53MAPTSMN1; SMN2ABCG2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | claimed |
| EP-1786425-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SmithKline Beecham Corporation (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2007002051-A1 | CARBOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF FLAVIVIRIDAE INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-04 | — | — | WO | claimed |
| WO-2006015035-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-09 | — | — | WO | claimed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1786425-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SmithKline Beecham Corporation (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007002051-A1 | CARBOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF FLAVIVIRIDAE INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006015035-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | TP53 15/4885MAPT 3300/4885SMN1; SMN2 3502/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | TP53 16/4885MAPT 3328/4885SMN1; SMN2 3473/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | TP53 16/4885MAPT 3328/4885SMN1; SMN2 3473/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | TP53 52/4885MAPT 3997/4885SMN1; SMN2 3261/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | TP53 1818/4885MAPT 2964/4885SMN1; SMN2 4373/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | TP53 1710/4885MAPT 2901/4885SMN1; SMN2 4142/4885 |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | TP53, POLI, PCNA | TP53 1/4885MAPT 4453/4885SMN1; SMN2 4792/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | TP53 448/4885MAPT 2854/4885SMN1; SMN2 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.